Efatutazone, a third-generation PPARγ agonist, has been reported to inhibit esophageal squamous cell carcinoma (ESCC) cell proliferation in vitro and in vivo through increased p21Cip protein levels via inactivation of Akt [28]. Here, AKT1 is linked to esophageal squamous cell carcinoma.